Trial Profile

Long-Term Open-Label Safety Study With SkyePharma FlutiForm HFA pMDI [SkyePharma Flutiform(TM) formoterol/fluticasone propionate hydrofluoroalkane pressurised metered dose inhaler] (100/10 microg and 250/10 microg) in adult and adolescent patients with asthma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 May 2008 Results will be presented at the American Thoracic Society in Canada.
27 Feb 2008 Status changed from in progress to completed, according to ClinialTrials.gov
29 Sep 2006 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com